AMGN vs. GILD, BIIB, SGEN, MRNA, MDT, ISRG, SNY, ELV, SYK, and BMY
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Biogen (BIIB), Seagen (SGEN), Moderna (MRNA), Medtronic (MDT), Intuitive Surgical (ISRG), Sanofi (SNY), Elevance Health (ELV), Stryker (SYK), and Bristol-Myers Squibb (BMY). These companies are all part of the "medical" sector.
Amgen vs.
Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.
Amgen pays an annual dividend of $8.52 per share and has a dividend yield of 3.9%. Gilead Sciences pays an annual dividend of $3.00 per share and has a dividend yield of 3.9%. Amgen pays out 57.9% of its earnings in the form of a dividend. Gilead Sciences pays out 67.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
75.5% of Amgen shares are held by institutional investors. Comparatively, 78.7% of Gilead Sciences shares are held by institutional investors. 0.6% of Amgen shares are held by insiders. Comparatively, 0.2% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Amgen has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.
Gilead Sciences received 949 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 77.92% of users gave Gilead Sciences an outperform vote while only 72.99% of users gave Amgen an outperform vote.
Amgen currently has a consensus price target of $250.94, suggesting a potential upside of 13.89%. Gilead Sciences has a consensus price target of $91.00, suggesting a potential upside of 19.25%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Amgen.
Amgen has a net margin of 30.23% compared to Gilead Sciences' net margin of 20.65%. Amgen's return on equity of 248.47% beat Gilead Sciences' return on equity.
In the previous week, Gilead Sciences had 4 more articles in the media than Amgen. MarketBeat recorded 24 mentions for Gilead Sciences and 20 mentions for Amgen. Gilead Sciences' average media sentiment score of 0.46 beat Amgen's score of 0.04 indicating that Gilead Sciences is being referred to more favorably in the news media.
Amgen has higher earnings, but lower revenue than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Gilead Sciences beats Amgen on 11 of the 20 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
